Apr 20, 2026 09:02AM Lucid Capital Markets Downgrades Passage Bio Inc. (PASG) to Neutral

Apr 20, 2026 07:03AM Passage Bio reports interim trial data, initiates strategic review

Mar 31, 2026 02:12AM Baird Starts Passage Bio Inc. (PASG) at Outperform

Mar 30, 2026 04:02PM Oppenheimer Starts Passage Bio Inc. (PASG) at Outperform

Nov 24, 2025 06:36AM Lucid Capital Markets Starts Passage Bio Inc. (PASG) at Buy, PT $68

Aug 14, 2025 06:57AM Passage Bio Inc. (PASG) PT Lowered to $10 at Guggenheim

Aug 14, 2025 06:43AM Passage Bio Inc. (PASG) PT Lowered to $67 at Canaccord Genuity

Jul 10, 2025 07:01AM Passage Bio announces 1-for-20 reverse stock split effective July 14

Jun 23, 2025 07:01AM Passage Bio (PASG) Reports Updated Interim Data from upliFT-D Study and Provides Program Update

May 13, 2025 05:43PM Passage Bio, Inc. (PASG) Reports In-Line Q1 EPS

Mar 4, 2025 04:13PM Passage Bio Inc. (PASG) PT Lowered to $6 at Chardan Capital Markets

Jan 10, 2025 07:11AM Passage Bio (PASG) Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Nov 13, 2024 04:30PM Passage Bio, Inc. (PASG) Misses Q3 EPS by 8c

Oct 24, 2024 07:02AM Passage Bio (PASG) Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN

Oct 24, 2024 07:00AM Passage Bio (PASG) Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN

Sep 17, 2024 06:42AM Canaccord Genuity Reiterates Buy Rating on Passage Bio Inc. (PASG)

Sep 10, 2024 07:53AM Passage Bio (PASG) Welcomes Tom Kassberg to Board of Directors

Aug 8, 2024 08:46AM Passage Bio, Inc. (PASG) Tops Q2 EPS by 5c

Aug 1, 2024 07:05AM Passage Bio (PASG) Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Jul 16, 2024 07:00AM Passage Bio (PASG) Receives Positive FDA Feedback on Expansion of upliFT-D Trial of PBFT02